A hidden Alzheimer’s tipping point may decide who gets dementia

When you hear the word “Alzheimer’s,” you probably picture plaques and tangled tau proteins crowding the brain. Yet, anyone who has met a centenarian who still remembers birthdays can tell you that those hallmarks don’t always equal lost memory.

That paradox drove a team of scientists from VIB, KU Leuven, the UK‑DRI and Muna Therapeutics to dig deeper. By examining donated brain tissue from older adults—some with dementia, some cognitively intact, and a few who lived past 100—they uncovered a surprising pattern: it isn’t just how many plaques pile up, but how the brain’s resident immune cells, the microglia, respond that matters.

Microglia are the brain’s house‑keepers and first responders. Early in Alzheimer’s, they swing into an inflammatory mode, trying to mop up amyloid‑β plaques. Later, a different cohort of microglia steps forward, presenting antigens—a kind of cellular billboard—to the rest of the immune system as tau tangles appear. The researchers call this the “tipping point.” If the shift toward the antigen‑presenting state happens, it seems to set the stage for neuronal loss and, eventually, dementia.

What’s fascinating is that not everyone follows the same script. People in their 80s who had plenty of amyloid but no dementia stayed stuck in the early, plaque‑focused microglial state. In contrast, many of the 100‑plus participants moved into the later antigen‑presenting phase, yet they didn’t suffer the usual tau‑linked damage. It’s as if their brains found a way to repurpose a normally harmful response into something protective.

These observations emerged thanks to two cutting‑edge techniques: spatial transcriptomics and single‑cell sequencing. By mapping gene activity in individual cells while preserving their anatomical context, the team identified six distinct tissue “domains” that corresponded to different disease stages. One domain marked the critical transition from plaque‑dominant to tau‑dominant pathology, and that shift coincided with the microglial makeover.

Why does this matter for patients? Current Alzheimer’s drugs largely chase plaques, hoping that clearing them will halt the disease. The new findings suggest a complementary strategy: nurture the early, beneficial microglial response or, better yet, steer the cells away from the harmful later state. Targets like the TREM2 pathway—already known to influence microglial activity—could become the focus of next‑generation therapies aimed at extending the brain’s natural resilience.

Timing, as always, appears crucial. Intervening before the immune shift locks onto tau may preserve cognition longer, perhaps even indefinitely for some. As Niels Plath, chief scientific officer at Muna Therapeutics, puts it, “We’re looking to boost resilience rather than just clean up plaques.”

In short, the study adds a nuanced layer to our understanding of Alzheimer’s: it’s not just the amount of pathology that decides fate, but the brain’s own immune choreography. Future research will need to confirm whether nudging microglia back toward a protective mode can indeed keep dementia at bay.